Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pegfilgrastim + Tivantinib + Topotecan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pegfilgrastim | Neulasta | GCSF-SD01 | Neulasta (Pegfilgrastim) is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary). | |
Tivantinib | ARQ197|ARQ 197|ARQ-197 | MET Inhibitor 59 | Tivantinib (ARQ197) inhibits MET and may have antimitotic activity, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 29924867, PMID: 28246274). | |
Topotecan | Hycamtin | Topotecan Hcl | Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01654965 | Phase I | Pegfilgrastim + Tivantinib + Topotecan | Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |